COMPLETE CITATION
Citation and identifiers
Rogawski DS, et al.. “Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.” Nature Communications. 12:2792 · doi:10.1038/s41467-021-23152-6.
- PubMed ID
- 33990599 ↗
RESEARCH QUESTION
Can first-in-class chemical probes inhibit ASH1L catalytic activity and produce anti-leukemic effects in leukemia models?
The study establishes catalytic inhibition in leukemia models, a direction that does not supply a treatment rationale for an ASH1L reduced-dosage neurodevelopmental disorder.
INTERPRETATION BOUNDARY
Read the finding and limit together.
What this study supports
Develops chemical probes that inhibit ASH1L catalytic activity in leukemia models.
What it cannot establish
ASH1L-related NDD is primarily a reduced-dosage disorder; an ASH1L inhibitor is not a therapeutic rationale for haploinsufficiency.
OPEN THE STUDY